


What's the HTA ESIG doing to prepare for EU HTA?

Emma Crawford (MSD), Anders Gorst-Rasmussen (Novo Nordisk), Sandro Gsteiger (Roche), Kirsten H. Herrmann (Pharming Group), Katrin Kupas (BMS), Martin Scott (Numerus), Fred Sorenson (Xcenda) - on behalf of HTA European Special Interest Group, sponsored by PSI and EFSPi




What are high-level EU HTA pain points that the ESIG identifies – and how are we addressing them?

An urgent need for collaboration and bridging – within and across disciplines

Insufficient training in advanced HTA statistical methodology and thinking

Practical and scientific challenges that pharma statisticians are uniquely positioned to advise on



- 3 white papers in development

- Participation at relevant conferences/events (ISPOR, DIA, PSI, EFSPi)

- Podcasts with The Effective Statistician¹
- 1 webinar in 2022, 2 webinars in development
- HTA handbook update in progress
- HTA training for PSI (& beyond!)

- Cross-ESIG collaborations
- Representing EFSPi at the European Commission HTA Stakeholders Network

- Communicating about methodological aspects (eg, EUnetHTA21 public consultations)



- Communications is overarching!**
- Leading active discussions on LinkedIn
 - Collaborating with relevant professional societies
 - Promoting our activities via PSI and EFSPi communication channels
- See our HTA ESIG webpage for latest updates!**



What are **YOUR** EU HTA pain points – and how can the ESIG help **YOU** address them?

Share your answers on a Post-it here!

¹<https://theeffectivestatistician.com/>

CHMP = Committee for Medicinal Products for Human Use, EC = European Commission, ESIG = European Special Interest Group, HTA = Health Technology Assessment, JCA = Joint Clinical Assessment, PICO = Population, Intervention, Comparators, Outcome

